2-叔丁氧基乙酸叔丁酯 | 55666-48-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-叔丁氧基乙酸叔丁酯
• 英文名称: 2-t-butoxyacetic acid t-butyl ester
• 英文别名: t-butyl t-butoxyacetate；tert.-Butyloxy-essigsaeure-tert.-butylester；tert-Butyl-tert-butoxyacetat；Tert-butyl 2-(tert-butoxy)acetate；tert-butyl 2-[(2-methylpropan-2-yl)oxy]acetate
• CAS: 55666-48-3
• 化学式: C₁₀H₂₀O₃
• mdl: MFCD26054310
• 分子量: 188.267
• InChiKey: OMOFILQTWANXFM-UHFFFAOYSA-N

物化性质

• 沸点：
  47-53 °C
• 密度：
  0.924±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-叔丁氧基乙酸叔丁酯 在 碳酸氢钠 作用下， 生成 tert-butyl glyoxylate
  参考文献：
  名称：

  Intramolecular reactions of 1-allylic 2,2-dimethyl ethylenetricarboxylates

  摘要：

  DOI：

  10.1021/ja00514a026
• 作为产物：
  描述：

  羟基乙酸 、 异丁烯 在 硫酸 作用下， 生成 2-叔丁氧基乙酸叔丁酯
  参考文献：
  名称：

  Intramolecular reactions of 1-allylic 2,2-dimethyl ethylenetricarboxylates

  摘要：

  DOI：

  10.1021/ja00514a026

文献信息

• Substituted Fused Pyrimidine Compounds
  申请人：Palle Venkata

  公开号：US20120115864A1

  公开（公告）日：2012-05-10

  The present invention discloses substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.

  本发明公开了式(I)的取代融合嘧啶化合物，它们的互变异构体、多晶形态、立体异构体、溶剂合物、药学上可接受的盐或含有它们的药物组合物，以及治疗由腺苷受体(AR)活性介导的疾病和病况的方法。本发明的化合物在治疗、预防或抑制可能通过腺苷受体拮抗而得到改善的疾病和疾病中具有用处，如哮喘、慢性阻塞性肺疾病、血管生成、肺纤维化、肺气肿、过敏性疾病、炎症、再灌注损伤、心肌缺血、动脉粥样硬化、高血压、充血性心力衰竭、视网膜病变、糖尿病、肥胖、炎症性胃肠道疾病和/或自身免疫性疾病。
• [EN] PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS<br/>[FR] PROCEDE DE PRODUCTION D'ACIDES 3-(4-HYDROXYPHENYL)PROPIONIQUES OPTIQUEMENT ACTIFS
  申请人：TAKASAGO PERFUMERY CO LTD

  公开号：WO2005051882A1

  公开（公告）日：2005-06-09

  The present invention relates to a process for producing an optically active 3-(4-hydroxyphenyl)propionic acid useful as intermediates for medicines, through short steps in good yield and with high optical purity. More specifically, the present invention relates to a process for producing an optically active 3-(4-hydroxyphenyl)propionic acid of the formula (6): wherein R2 is an alkyl group; R5 to R8 are each independently a hydrogen atom or a substituent; and the symbol * is an chiral carbon atom, or a salt thereof, which comprises reacting a benzaldehyde of the formula (1): wherein R1 is a protective group; and R5 to R8 are each the same as defined above, with a glycolic acid derivative of the formula (2): wherein R3 is a hydrocarbon group; and R2 is the same as defined above, hydrolyzing the resulting product to give a cinnamic acid of the formula (4): wherein R1, R2 and R5 to R8 are each the same as defined above, or a salt thereof, and subjecting the resulting cinnamic acid (4) or a salt thereof to asymmetric hydrogenation to give an optically active phenylpropionic acid of the formula (5): wherein all the symbols are each the same as defined above, or a salt thereof, followed by deprotection.

  本发明涉及一种生产光学活性3-(4-羟基苯基)丙酸的工艺，作为药物中间体，通过简短的步骤、高产率和高光学纯度。更具体地，本发明涉及一种生产光学活性3-(4-羟基苯基)丙酸的工艺，其化学结构如下（6）：其中R2是烷基；R5至R8分别独立地是氢原子或取代基；符号*是一个手性碳原子，或其盐，包括将化学结构如下（1）的苯甲醛：其中R1是保护基；R5至R8分别与上述定义相同，与化学结构如下（2）的甘醇酸衍生物反应：其中R3是烃基；R2与上述定义相同，水解得到肉桂酸的产物：其中R1、R2和R5至R8分别与上述定义相同，或其盐，并将得到的肉桂酸（4）或其盐进行不对称氢化反应，得到光学活性苯丙酸的产物：其中所有符号均与上述定义相同，或其盐，随后进行去保护处理。
• Highly Stereocontrolled Construction of 3-Alkoxyazetidin-2-ones Using Ester Enolate-Imine Condensation
  作者：Makoto Shimizu、Takenori Ishida、Tamotsu Fujisawa

  DOI：10.1246/cl.1994.1403

  日期：1994.8

  5-dimethoxymethyl-2-methyl-1,3-dioxolane ring as a chiral auxiliary could be controlled by the enolate metals, the ester parts, and the alkoxy groups. Addition of the titanium enolate provided (3R,4S)-3-alkoxyazetidin-2-one exclusively, while the corresponding (3R,4R)-isomer was obtained predominantly by the condensation using the zinc enolate of t-butyl α-benzyloxy-, phenoxy-, or t-butoxyacetate with the chiral imine

  α-烷氧基乙酸酯的烯醇化物与具有 (4S,5S)-4,5-二甲氧基甲基-2-甲基-1,3-二氧戊环作为手性助剂的手性亚胺的非对映选择性加成反应可以通过烯醇化物金属来控制，酯部分和烷氧基。添加钛烯醇化物仅提供 (3R,4S)-3-alkoxyazetidin-2-one，而相应的 (3R,4R)-异构体主要通过使用叔丁基 α-苄氧基-的烯醇锌缩合获得，苯氧基-或叔丁氧基乙酸酯与手性亚胺。
• BIOCOMPATIBLE AND BIODEGRADABLE ELASTOMERIC POLYMERS
  申请人：Pattanaik Asima

  公开号：US20100003305A1

  公开（公告）日：2010-01-07

  Disclosed herein are biocompatible and biodegradable polymers comprising one or more ECM-mimetic peptides and one or more biodegradable moieties, wherein the moieties do not comprise an amino acid or residue thereof. Further disclosed herein are methods for making and using the disclosed biocompatible polymers.

  本文披露了一种生物相容性和可生物降解的聚合物，其中包括一种或多种ECM-mimetic肽和一种或多种可生物降解的基团，其中基团不包括氨基酸或其残基。本文还披露了制备和使用所述生物相容性聚合物的方法。
• Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids
  申请人：Yokozawa Tohru

  公开号：US20070142472A1

  公开（公告）日：2007-06-21

  The present invention relates to a process for producing an optically active 3-(4-hydroxyphenyl)propionic acid useful as intermediates for medicines, through short steps in good yield and with high optical purity. More specifically, the present invention relates to a process for producing an optically active 3-(4-hydroxyphenyl)propionic acid of the formula (6): wherein R 2 is an alkyl group; R 5 to R 8 are each independently a hydrogen atom or a substituent; and the symbol * is an chiral carbon atom, or a salt thereof, which comprises reacting a benzaldehyde of the formula (1): wherein R 1 is a protective group; and R 5 to R 8 are each the same as defined above, with a glycolic acid derivative of the formula (2): wherein R 3 is a hydrocarbon group; and R 2 is the same as defined above, hydrolyzing the resulting product to give a cinnamic acid of the formula (4): wherein R 1 , R 2 and R 5 to R 8 are each the same as defined above, or a salt thereof, and subjecting the resulting cinnamic acid (4) or a salt thereof to asymmetric hydrogenation to give an optically active phenylpropionic acid of the formula (5): wherein all the symbols are each the same as defined above, or a salt thereof, followed by deprotection.

  本发明涉及一种生产光学活性的3-(4-羟基苯基)丙酸的方法，该方法通过短步骤以良好产率和高光学纯度的方式，作为药物中间体。更具体地说，本发明涉及一种生产式(6)的光学活性3-(4-羟基苯基)丙酸的方法：其中R2是烷基；R5到R8分别独立地是氢原子或取代基；符号*是手性碳原子，或其盐，包括用式(1)的苯甲醛反应：其中R1是保护基；R5到R8分别与上述定义相同，与式(2)的乙二醇酸衍生物反应：其中R3是碳氢基团；R2与上述定义相同，水解所得产物得到式(4)的肉桂酸：其中R1、R2和R5到R8分别与上述定义相同，或其盐，并将所得的肉桂酸(4)或其盐经过不对称氢化作用得到式(5)的光学活性苯丙酸：其中所有符号均与上述定义相同，或其盐，然后去保护基。